MondayMorning

View more issues:

Articles in June 8, 2009 issue of MondayMorning

• Council of Economic Advisers
• Weekly stock performance
• American Medical Association
• Markets: stocks ended a volatile day Friday little changed after the government reported a spike in the unemployment rate to 9.4% in May, the highest level in more than 25 years, even as the pace of layoffs eased more than expected
• Pfizer Inc. , the world's largest drugmaker, is acquiring Wyeth for $65 billion. Merck & Co. is spending about $44 billion to buy rival Schering-Plough Corp. . Bristol-Myers in March formed a group of top managers to pursue deals and drug developmen
• Public healthcare option meets bipartisan resistance
• Few cancer breakthroughs reported at major meeting
• FDA aims to make its decisions more transparent
• XTENT, Inc
• Antigenics Inc
• Palomar Medical Technologies Inc
• Baxter International Inc
• Antipsychotic drugs made by Pfizer Inc. , AstraZeneca Plc and Eli Lilly & Co. work in teens and adolescents and have side effects "similar" to those seen in adults, the U.S. Food and Drug Administration said
• Aetna cuts 2009 forecast on higher medical costs
• Sanofi lands cancer drug with $1 Billion estimated 2012 sales
• UBS says Bristol-Myers not in talks for Elan Stake
• GlaxoSmithlike Plc has boosted its early-stage drug pipeline by signing a potential $1 billion deal with privately held U.S. biotech company Concert Pharmaceuticals Inc. to access deuterium-containing medicines
• Amylin Pharmaceuticals Inc. , maker of the diabetes drug Byetta, said shareholders ousted chairman Joseph Cook and elected two board nominees proposed by critics Eastbourne Capital Management LLC and Carl Icahn
• Eli Lilly & Co said use of its Alimta following successful chemotherapy treatment helped patients with advanced lung cancer live significantly longer
• Northfield Laboratories Inc. , whose human red blood cell substitute was denied U.S. Food and Drug Administration approval, filed for bankruptcy protection last week to liquidate its assets
• Almirall SA
• ARCA biopharma Inc
• Financing: Swiss pharmaceuticals giant Novartis AG may pass on a chance to buy a majority stake in eye-care company Alcon Inc. for $28.2 billion after Alcon shares slumped, Chief Executive Officer Daniel Vasella said last week.
• Weekly key rates
• A treatment designed to harness the body's immune system to fight cancer appeared to thwart two forms of the malignancy in studies, boosting prospects for weapons against the disease that act like vaccines
• Roche Holding AG's Herceptin, a breast cancer drug that targets the HER-2 gene, added almost three months of life to stomach cancer patients in a study that may expand use of DNA testing to that malignancy
• In patients with chronic stroke and impaired hand movements, electrical somatosensory stimulation of the median nerve of the affected hand appears to enhance motor function, according to results of a small study conducted in Germany
• A gene that is highly active in up to 20% of breast cancer cases might be blocked by a generically available blood pressure drug, US researchers reported
• Medical bills are behind more than 60% of US personal bankruptcies, US researchers reported on Thursday in a report they said demonstrates that healthcare reform is on the wrong track
• AstraZeneca Plc's MedImmune biotechnology unit has won an initial $90 million order from the US government to make a live attentuated vaccine against the new H1N1 flu strain, it said last week
• Britain's healthcare cost-effectiveness watchdog has recommended Merck KGaA's drug Erbitux be used on the state health service for treating some colon cancer patients after surgery
• GlaxoSmithKline Plc
• Oculus Innovative Sciences Inc
• California's $3 billion stem-cell funding agency wants to get 10 to 12 new therapies into human testing within four years, said the agency's president, Alan Trounson